Insurers cut GLP‑1s

Health insurers are cutting back coverage for Wegovy and Zepbound, leaving many patients to switch drugs, stop treatment, or pay the full price themselves. (goodrx.com) GoodRx reported that from 2025 to 2026, about 12 million people lost coverage for Zepbound and another 12 million lost coverage for Wegovy under commercial insurance plans. Its latest tracker says more than 41 million people now have no commercial coverage for Wegovy and more than 109 million have no coverage for Zepbound. (goodrx.com) NPR reported on April 22 that patients are being told mid-treatment that their plans no longer cover the drugs or now require new prior authorizations and tighter rules. Maine Public, which carried the NPR report, said some patients are paying out of pocket after appeals fail. (text.npr.org, mainepublic.org) These medicines are prescribed for obesity and work by mimicking gut hormones that help people feel full and eat less. Wegovy is Novo Nordisk’s semaglutide product for weight loss, and Zepbound is Eli Lilly’s tirzepatide product for weight loss. (goodrx.com, goodrx.com) Coverage has been uneven for years, but employers and insurers have been rechecking benefits as demand and spending climbed. KFF said in October 2025 that large employers were weighing whether to scale back coverage or add stricter requirements because of the drugs’ cost. (kff.org) The restrictions are not just outright exclusions. GoodRx said only 4% of commercially insured people have unrestricted coverage for Zepbound and 9% have unrestricted coverage for Wegovy, meaning most patients face prior authorization, step therapy, quantity limits, or other hurdles. (goodrx.com, web.primetherapeutics.com) The money involved is large enough to change treatment decisions. GoodRx said the average insured person taking Zepbound can expect to pay more than $1,400 a year in copays, and retail prices can run above $1,400 per prescription without insurance. (goodrx.com) Patients have had fewer fallback options since federal regulators declared shortages over for the branded drugs, which limited routine compounding of copycat versions. GoodRx said pharmacies and prescribers generally can no longer keep dispensing regular compounded tirzepatide injections now that the shortage has ended. (goodrx.com) Government coverage remains a separate fight. NPR reported in November 2024 that the Biden administration proposed expanding Medicare and Medicaid coverage for obesity drugs, but those drugs had long been excluded from mandatory coverage, and private insurance decisions still determine access for millions of workers and their families. (mainepublic.org) For patients who started these drugs when coverage was broader, the practical question now is whether their next refill is still on the formulary — or whether the same prescription suddenly costs four figures. (text.npr.org, goodrx.com)